These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 26082780)
1. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Datta J; Berk E; Cintolo JA; Xu S; Roses RE; Czerniecki BJ Front Immunol; 2015; 6():271. PubMed ID: 26082780 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Mac Keon S; Ruiz MS; Gazzaniga S; Wainstok R Front Immunol; 2015; 6():243. PubMed ID: 26042126 [TBL] [Abstract][Full Text] [Related]
5. On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ Front Oncol; 2019; 9():50. PubMed ID: 30788290 [TBL] [Abstract][Full Text] [Related]
7. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy. Gomella LG; Gelpi-Hammerschmidt F; Kundavram C Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724 [TBL] [Abstract][Full Text] [Related]
8. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Quinn DI; Shore ND; Egawa S; Gerritsen WR; Fizazi K Urol Oncol; 2015 May; 33(5):245-60. PubMed ID: 25575714 [TBL] [Abstract][Full Text] [Related]
10. Antigen delivery by dendritic cells. Moll H Int J Med Microbiol; 2004 Oct; 294(5):337-44. PubMed ID: 15532992 [TBL] [Abstract][Full Text] [Related]
11. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy. Salem ML Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies. Patel A; Fong L Oncology (Williston Park); 2018 Jun; 32(6):e65-e73. PubMed ID: 29940064 [TBL] [Abstract][Full Text] [Related]
14. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer. Xu P; Wasielewski LJ; Yang JC; Cai D; Evans CP; Murphy WJ; Liu C Biomedicines; 2022 Jul; 10(8):. PubMed ID: 35892678 [TBL] [Abstract][Full Text] [Related]
15. Dendritic cell-based vaccine efficacy: aiming for hot spots. Pizzurro GA; Barrio MM Front Immunol; 2015; 6():91. PubMed ID: 25784913 [TBL] [Abstract][Full Text] [Related]